about
P1889
Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor betaSynthesis and antiviral properties of 9-[(2-methyleneaminoxyethoxy)methyl]guanine derivatives as novel Acyclovir analoguesSynthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand.Curaxins: a new family of non-genotoxic multitargeted anticancer agents.Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.Estrogen receptor ligands: a patent review update.CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes.Identification of new Fyn kinase inhibitors using a FLAP-based approach.Estrogen receptor β ligands: recent advances and biomedical applications.Ceramide analogues in apoptosis: a new strategy for anticancer drug development.Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents.Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model.Anticancer agents that counteract tumor glycolysis.Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffoldsDual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor.Small-molecule inhibitors of human LDH5.An update on therapeutic opportunities offered by cancer glycolytic metabolism.Constituents of Polygala flavescens ssp. flavescens and Their Activity as Inhibitors of Human Lactate Dehydrogenase.Risks and benefits related to alimentary exposure to xenoestrogens.Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer.Identification and characterization of a new reversible MAGL inhibitor.Anticancer agents interacting with membrane glucose transporters.Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells.Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxiaN-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation.Antiproliferative activity and cell cycle analysis of 2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole on MCF-7 breast and HCT-15 colon cancer cell lines.Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells.Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties.Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours.Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta.Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents.Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells.New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring.Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties.Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase.BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides.
P50
Q28306027-7376685C-0A63-4B0C-80B8-6377DB17584DQ28377690-4DDC0209-8F0F-48AD-B3CC-0CE5BB752328Q32020751-7BF78B06-DCA0-4440-84F4-CF5AD965B5E7Q34061949-543AF6E8-23FE-40ED-8913-7B0ED3D37621Q34315419-B0532B03-7AF9-4C90-94EC-C8421C14EB8EQ34347152-BB18D870-32EF-49F5-A060-9A110971F318Q34525138-BD08C7D6-BED4-41ED-AFAA-435313A02C4AQ34930830-1C64AB09-FE09-435E-A438-96F7ACEA3B0CQ34977657-B71C26D8-2365-4AF5-9500-717D669CCA6EQ35016384-0E0156DB-53BC-4FC7-BC49-5953A81AAB90Q35079308-EFA67B7A-7211-412E-985D-4930BCD521DAQ35836244-F0BD8F34-C8E2-4D6E-BBE7-8530870E1569Q36175547-A2063E1C-694F-47DB-975A-1533B0594AACQ36452381-2C845FA2-936D-472F-9691-FDE436EB381BQ37310087-328B57A4-0B03-4DB5-92BE-5B4EAAA532D2Q37575221-54C7BAF9-59B3-4E3B-B57A-C2D5136A68CDQ37634356-6410E00E-E7F2-4034-A38F-8C59DD5C39CAQ38257405-548D9314-13D8-4F79-B097-F8B57953D1B9Q38686527-78A45576-A45C-4568-8211-83719DAFA70BQ38690249-C125EEB5-EF44-4849-B3F7-FBCC8B6B7B77Q38699260-1179507E-508C-45A7-89A0-D6183425677EQ38992675-8FAE4796-303F-48A1-8A10-D0835B75C6A7Q39064468-B53CD800-2AB7-4FF8-8C83-6ACF3887E9F0Q39066242-1F9DDF97-57A3-4085-9931-52D2B2CC986AQ39068039-5B2F5E61-BE19-4E5B-9929-5EA15872A593Q39468979-8A486BD1-CDBE-45F0-A5A2-7FDB6E802758Q39570539-38780346-943F-4D2D-AB19-5673E17C1B85Q39589847-6F442B50-D287-411D-9D9D-3EA9F6DBDC5CQ39664910-3374EE69-B011-4C10-82B9-3B5B41E4E806Q39693708-12A6C621-E4D1-411C-A1CC-B62555FE6A5DQ39811801-E2E5C561-E892-4A99-AE9C-97CC0BC12654Q39985659-DA2C3ABD-3850-44F2-8416-4B02B5C18719Q40013982-58BA2D3A-FA9E-44CD-99E5-38928F217F6AQ40265085-B8AA50C1-E2C0-475B-B254-71E8D6797FF2Q40357881-EFEC43C4-88AB-4645-BE61-A2FE50C6CD65Q40567576-55899181-3D1D-4578-9360-E8D43CDF95A9Q40666140-98427E08-611D-4307-9D9B-27FC8192C59BQ40717222-66708D25-A1BF-4723-8740-F5E01CD453AFQ41044824-F9AA1AB6-9EE3-486E-9EB5-6FB6CD709589Q42863775-73DF1699-C24B-41FA-B3E8-1FDB0808EA9B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Filippo Minutolo
@ast
Filippo Minutolo
@en
Filippo Minutolo
@es
Filippo Minutolo
@nl
Filippo Minutolo
@sl
type
label
Filippo Minutolo
@ast
Filippo Minutolo
@en
Filippo Minutolo
@es
Filippo Minutolo
@nl
Filippo Minutolo
@sl
altLabel
F Minutolo
@en
prefLabel
Filippo Minutolo
@ast
Filippo Minutolo
@en
Filippo Minutolo
@es
Filippo Minutolo
@nl
Filippo Minutolo
@sl
P1053
A-7480-2011
P106
P1153
7004587084
P1889
P21
P31
P3829
P496
0000-0002-3312-104X